OHM-- just to be clear about "misleading statement

OHM-- just to be clear about "misleading statements"

you state --"Using the excuse of receptor occupancy when other HIV drugs have not been held to that standard" So Ibalizumab got approved for HIV in 2018. They provided RO results. From the NEJM:
https://www.nejm.org/doi/full/10.1056/NEJMoa1711460
_________________________________________________________________
"PHARMACOKINETIC AND PHARMACODYNAMIC FEATURES"
"The population mean receptor occupancy (the proportion of CD4 receptors that were occupied by ibalizumab) remained at more than 85% throughout the period of study-drug administration. The proportion of patients with at least 85% receptor occupancy was 97% on day 21 and 81% at week 25."
__________________________________________________________________
you state--" NASH trial fully enrolled with results in 2020. Cancer trials completing enrollment with possible results 2020."--I would hope that is typo instead of cut paste from cydy website??
__________________________________________________________________Several things you just seem upset with the way a FACT was stated?? I.E.-- They stated "total compensation" Is that not true?? Is some of that to be returned in the latest "unjust enrichment" settlement?? TOTAL means total.

you know what they say--never let facts get in the way of a good opinion